| Darzalex (daratumumab) / J&J |
NCT03768960: A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent |
|
|
| Completed | 4 | 150 | RoW | Daratumumab, DARZALEX | Johnson & Johnson Private Limited | Multiple Myeloma | 07/22 | 07/22 | | |
ChiCTR2100052302: A multi-center, prospective, randomized controlled trial of the efficacy of Marphalan combined with Daratumomab as a pretreatment regimen for autologous hematopoietic stem cell transplantation in the treatment of high-risk multiple myeloma |
|
|
| Not yet recruiting | 4 | 50 | | malphalan combined with CD38 monoclonal antibody (daratumumab) ;malphalan | Hematology Center of the First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, Self-funded | Multiple Myeloma | | | | |
ChiCTR2100049253: A prospective, nonrandomized, exploratory clinical study of low-frequency daratumumab in the treatment of light-chain amyloidosis (AL) |
|
|
| Not yet recruiting | 4 | 47 | | daratumumab | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, SCI Paper Fund | light chain amyloidosis | | | | |
MMY4032, ChiCTR2200055491: Clinical outcomes of Chinese patients with multiple myeloma receiving daratumumab: a non-interventional observational study (registry study) |
|
|
| Recruiting | 4 | 490 | | Nil | Peking University People's Hospital; West China Hospital of Sichuan University, Xi'an Janssen Pharmaceutical Ltd. | Multiple Myeloma (MM) | | | | |
ChiCTR2300075660: A single-center, prospective, single-arm clinical study of daratumumab combined with bortezomib, lenalidomide, dexamethasone, and doxorubicin (Dara-VRdA) followed by autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma |
|
|
| Not yet recruiting | 4 | 342 | | Bortezomib, doxorubicin, and dexamethasone (VAd) regimen induction chemotherapy for 2 cycles; daratumumab combined with bortezomib, lenalidomide, dexamethasone, and doxorubicin (Dara-VRdA) followed by autologous hematopoietic stem cell transplantation (ASCT) | Ruijin Hospital, Shanghai JiaoTong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, self-funded | Multiple myeloma | | | | |
AHA2023, NCT05849740: An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A |
|
|
| Recruiting | 4 | 10 | RoW | Daratumumab and corticosteroid treatment, Intervention arm | Institute of Hematology & Blood Diseases Hospital | Acquired Hemophilia | 04/27 | 10/27 | | |
ChiCTR2400086035: A prospective, multicenter, non-randomized, concurrent controlled study of the DVd regimen (Daratumumab + Bortezomib + dexamethasone) and VPd regimen (Bortezomib + Pomalidomide + dexamethasone) in newly diagnosed multiple myeloma patients with renal insufficiency |
|
|
| Not yet recruiting | 4 | 182 | | DVd(Daratumumab + Bortezomib + dexamethasone) regimen; VPd(Bortezomib + Pomalidomide + dexamethasone) regimen | The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital | Multiple myeloma with renal insufficiency | | | | |
